Although the physiological consequences of acetylation at K120 and K164 within the DNA-binding domain have been established in the studies of p53 acetylation-defective mutant mice^[@R10],[@R11]^, the *in vivo* functions of CTD acetylation remain elusive. Interestingly, by examining the mutant mice expressing C-terminal truncated forms of p53, two recent studies have shown that loss of the CTD results in p53 activation^[@R12],[@R13]^, suggesting that the CTD may act as a docking site for negative regulators of p53. Nevertheless, the identity of the negative regulators and the consequences of CTD acetylation remain unclear. To identify proteins that bind p53 in a manner dependent on its CTD acetylation status, we synthesized both unacetylated (Un-Ac) and fully-acetylated (Ac) biotin-conjugated CTD peptides and used the immobilized peptides as affinity columns to purify cellular factors ([Fig. 1a](#F1){ref-type="fig"}). As shown in [Fig. 1b](#F1){ref-type="fig"}, we failed to identify any proteins enriched in the acetylated p53 CTD column. Instead, coomassie blue staining of the bound fractions revealed a major band of \~38 kD from the unacetylated p53 column that was completely absent from the acetylated one. Mass spectrometry analysis of this band revealed 28 unique peptides identical to SET ([Fig. 1c](#F1){ref-type="fig"} and [Extended Data Fig. 1a](#F5){ref-type="fig"}), an oncoprotein that is activated by translocation-associated gene fusions in patients with acute myeloid leukemia^[@R14]^. Although a previous study reported an interaction between p53 and SET^[@R15]^, the impact of CTD acetylation on the functional consequences of this interaction remains unclear.

Acetylation-dependent disruption of the p53-SET interaction was confirmed *in vitro* with purified SET protein ([Fig. 1d](#F1){ref-type="fig"}). Moreover, expression of CBP, the enzyme responsible for CTD acetylation, completely abrogated the formation of SET complex with wildtype p53 (p53^WT^), but not with CTD acetylation-deficient p53 (p53^KR^) mutant, validating that CTD acetylation is crucial for the p53-SET interaction in cells ([Fig. 1e](#F1){ref-type="fig"}). Interestingly, other modifications on the CTD lysine residues, including methylation, ubiquitination, sumoylation and neddylation, had no dramatic effect on this binding, underscoring the specificity of acetylation-dependent control of p53-SET interactions ([Extended Data Fig. 1b-e](#F5){ref-type="fig"}).

Next, we tested whether SET acts as a transcriptional cofactor by forming a p53-SET complex on p53 target promoter. As shown in [Fig. 1f](#F1){ref-type="fig"}, although SET alone showed no obvious DNA binding activity, in the presence of both p53 and SET, a slower migrating SET/p53-DNA complex was formed and super-shifted by p53- or SET-antibody. Further binding-domain mapping indicate that the CTD of p53 directly interacts with the acidic domain (AD) of SET ([Extended Data Fig. 1f-h](#F5){ref-type="fig"}). To determine the impact of SET on the transcriptional activity of p53, we measured transactivation of a p53-responsive reporter gene. Indeed, p53-mediated transactivation was abrogated upon co-expression of wildtype SET, but not a SET mutant lacking the acidic domain required for p53 binding ([Fig. 1g](#F1){ref-type="fig"}). Conversely, wildtype SET-mediated repression was abrogated when a p53 mutant lacking the CTD was expressed ([Fig. 1g](#F1){ref-type="fig"}). Notably, the interaction of endogenous p53 and SET was easily detected in unstressed cells; however, upon DNA damage, despite increased p53 levels, the p53-SET interaction was largely diminished, likely due to the induction of CTD acetylation ([Fig. 1h](#F1){ref-type="fig"}). Moreover, chromatin immunoprecipitation (ChIP) assays revealed that the recruitment of SET to the promoter of p53 targets was largely inhibited ([Fig. 1i](#F1){ref-type="fig"} and [Extended Data Fig. 1i-k](#F5){ref-type="fig"}). Together, these data indicate that SET acts as a transcriptional co-repressor of p53 but acetylation of the CTD leads to abrogate the repression through disrupting the p53-SET interactions upon DNA damage ([Fig. 1j](#F1){ref-type="fig"}).

We further examined whether inactivation of SET influences the activities of p53 in human cancer cells. Indeed, RNAi-mediated depletion of SET markedly elevated the expression of p53 targets, such as p21 and PUMA, without affecting the steady-state levels of endogenous p53 in HCT116 colorectal carcinoma cells ([Fig. 2a](#F2){ref-type="fig"}). Similar effects were obtained in other human cancer cell lines that express wildtype p53, including MCF7 (breast carcinoma), U2OS (osteosarcoma), H460 (lung carcinoma) and SU-DHL-5 (B-cell lymphoma) ([Fig. 2b](#F2){ref-type="fig"}). Moreover, this induction of p21 and PUMA expression was completely abrogated in isogenic HCT116 *p53^−/−^* cells ([Fig. 2c](#F2){ref-type="fig"}), indicating that the SET-mediated effects are p53-dependent. Further analysis of U2OS and p53-null U2OS cells by SET knockdown identified a number of p53 targets that are upregulated upon inactivation of SET in a p53-dependent manner and SET knockdown induced p53-dependent cell growth repression in those cells ([Extended Data Fig. 2a-c](#F6){ref-type="fig"} and [Extended Data Fig. 3a-b](#F7){ref-type="fig"}). To examine the impact of SET on p53-mediated tumor suppression, we tested whether SET depletion affects cell growth in xenograft tumor models. As shown in [Fig. 2d](#F2){ref-type="fig"}, SET knockdown dramatically suppressed tumor growth of HCT116 cells, but not isogenic HCT116 *p53^−/−^* cells. Moreover, such p53-dependent effects were further validated in HCT116 p53 knockout cells generated by CRISPR/Cas9-mediated genome editing technique ([Extended Data Fig. 3c-e](#F7){ref-type="fig"}). These data indicate that the p53-SET interaction is crucial for the tumor growth suppression by p53.

Since SET apparently had no dramatic effect on protein stability, DNA binding, or acetylation levels of p53 ([Extended Data Fig. 4a-c](#F8){ref-type="fig"}), we examined whether SET suppressed p53-mediated transactivation by affecting the chromatin modifications at p53 target promoters. ChIP analysis revealed that SET depletion significantly increased the acetylation levels of H3K18 and H3K27 at *p21* and *PUMA* promoter without obviously affecting H3K9, H3K14, H4K16 or pan-H4 acetylation ([Fig. 2e](#F2){ref-type="fig"} and [Extended Data Fig. 4d](#F8){ref-type="fig"}). p300/CBP, which majorly targets H3K18 and H3K27 acetylation *in vivo*^[@R16],[@R17]^, acts as a key co-activator in p53-mediated transcriptional activation^[@R18]-[@R20]^. We then examined whether SET suppresses p300/CBP-mediated acetylation of H3K18 and H3K27 as SET had no obvious effect on the recruitment of p300/CBP ([Extended Data Fig. 4e](#F8){ref-type="fig"}). Indeed, *in vitro* acetylation assays revealed that SET effectively repressed p300-dependent acetylation of H3K18 and H3K27 ([Fig. 2f](#F2){ref-type="fig"}) and these finds were further verified on p53 target promoters by ChIP analysis ([Fig. 2g](#F2){ref-type="fig"} and [Extended Data Fig. 4f](#F8){ref-type="fig"}). Taken together, these data indicate that SET represses p53-mediated transactivation by inhibiting p300/CBP-dependent acetylation of H3K18 and H3K27 on p53 target promoters ([Fig. 2h](#F2){ref-type="fig"}).

Numerous studies indicate that lysine acetylation often creates docking sites for "reader" proteins that possess bromodomain, a structural motif that forms a recognition surface for acetylated lysine^[@R5],[@R6]^. Our analysis of the p53-SET interaction suggests that the acidic domain of SET serves as a "converse reader" that binds the lysine-rich CTD of p53 in a manner that can be specifically abrogated upon acetylation of these lysine residues. To further evaluate this model, we examined whether p53 interacts with other proteins in a similar manner. Several transcription cofactors known to interact directly with p53, including VPRBP, DAXX and PELP1 (refs. [@R7]-[@R9]), also contain acidic domains similar to that of the SET protein ([Fig. 3a](#F3){ref-type="fig"} and [Extended Data Fig. 5a](#F9){ref-type="fig"}). Their acidic domains also readily bound unacetylated, but not acetylated, p53 CTD ([Fig. 3b-d](#F3){ref-type="fig"}). Similar results were also obtained when the full-length proteins of VPRBP, DAXX and PELP1 were tested ([Extended Data Fig. 5b](#F9){ref-type="fig"}). More importantly, their interactions (VPRBP, DAXX and PELP1) with wildtype p53, but not the acetylation-deficient p53^KR^ mutant, were inhibited by CBP-induced acetylation in human cells ([Extended Data Fig. 5c-e](#F9){ref-type="fig"}).

Previous studies showed that SET also regulates the activities of several other cellular factors, including histone H3, KU70 and FOXO1, through direct interactions^[@R21]-[@R23]^. Notably, the binding regions of all three proteins contain a lysine-rich domain (KRD) similar to the CTD of p53 ([Fig. 3e](#F3){ref-type="fig"}). More importantly, those lysine residues have also been reported to be acetylated *in vivo*^[@R24]-[@R26]^. To test whether SET-mediated interactions with these factors are also regulated by acetylation, we performed *in vitro* binding assays of the acidic domain of SET with unacetylated vs. acetylated lysine-rich domain of H3, KU70 and FOXO1. Indeed, the acidic domain of SET interacted with unacetylated, but not acetylated, lysine-rich domains of H3, KU70 and FOXO1 ([Fig. 3f-h](#F3){ref-type="fig"}). Similar results were also obtained when the full-length SET protein was used in the binding assays ([Extended Data Fig. 5f-h](#F9){ref-type="fig"}), suggesting that the SET interactions with H3, KU70 and FOXO1 are abrogated by acetylation in a manner analogous to the p53-SET binding. Since VPRBP, DAXX and PELP1 are also implicated in transcription regulation, we examined whether these factors interact with H3 in a similar manner. Indeed, VPRBP, DAXX and PELP1 specifically bound unacetylated H3 whereas, as expected, bromodomain proteins such BRD4 and BRD7 recognized only acetylated H3 ([Extended Data Fig. 5i-j](#F9){ref-type="fig"}).

Above data indicate that this mechanism of acetylation-dependent regulation is widespread in nature. Since the positive charge within lysine-rich domain can attract the negative charge of the acidic domain, these lysine clusters form a docking site for acidic domain-containing regulators. However, upon acetylation, the positive charge of lysine sidechains is neutralized, abolishing the docking site for the acidic domain-containing regulators. Conversely, deacetylation of these lysine residues reverses the effects and promotes the recruitment of acidic domain-containing regulators ([Fig. 3i](#F3){ref-type="fig"}). Thus, unlike bromodomain readers, which preferentially bind the acetylated forms of their cognate ligands, the acidic domain readers specifically recognize the unacetylated forms of their ligands.

To corroborate this notion, we compared the SET-binding properties of the acetylation-deficient mutant p53^KR^ and an acetylation-mimicking mutant p53^KQ^ ([Extended Data Fig. 6a](#F10){ref-type="fig"}). As shown in [Extended Data Fig. 6b](#F10){ref-type="fig"}, the p53^KR^ mutant, like unacetylated p53, strongly bound SET; conversely, like acetylated p53, the p53^KQ^ mutant completely abolished the interaction with SET. Similar results were also obtained upon analysis of the acetylation-modulated interactions of p53 with VPRBP, DAXX and PELP1 ([Extended Data Fig. 6c-e](#F10){ref-type="fig"}).

To further determine the physiological significance of these interactions *in vivo*, we generated *p53^KQ/KQ^* mutant mice ([Extended Data Fig. 7a-d](#F11){ref-type="fig"}). While heterozygous *p53^+/KQ^* mice displayed normal postnatal development, *p53^KQ/KQ^* homozygous mice were neonatal lethal ([Extended Data Fig. 7e](#F11){ref-type="fig"}). All newborn *p53^KQ/KQ^* pups were slightly smaller than their *p53^+/+^* littermates ([Fig. 4a](#F4){ref-type="fig"}), lacked milk in their stomach and died within one day of birth, apparently due to dehydration from lack of maternal nourishment. In addition, live *p53^KQ/KQ^* mice also displayed uncoordinated movements, consistent with neurological impairments. Indeed, the brains of *p53^KQ/KQ^* mice appeared smaller than those of *p53^+/+^* mice ([Fig. 4b](#F4){ref-type="fig"}). Immunohistochemistry analysis of *p53^KQ/KQ^* brain sections revealed a marked induction of cleaved Caspase 3 staining without an obvious increase in p53 protein levels ([Fig. 4c](#F4){ref-type="fig"} and [Extended Data Fig. 7f](#F11){ref-type="fig"}), suggesting that the neurological defects of *p53^KQ/KQ^* mice may reflect increased apoptosis due to deregulation of the p53^KQ^ protein. In accord with this notion, the major apoptotic transcriptional targets of p53 (*Bax* and *Puma*) are significantly up-regulated in *p53^KQ/KQ^* brain tissue ([Fig. 4d](#F4){ref-type="fig"}). Indeed, various tissues of *p53^KQ/KQ^* mice displayed distinct patterns of induction of the different p53 target genes, suggesting tissue-specific activation of the target genes by p53^KQ^ *in vivo* ([Fig. 4d](#F4){ref-type="fig"}).

Notably, the p53-SET interaction was readily detected in *p53^+/+^*, but not *p53^KQ/KQ^*, MEFs ([Fig. 4e](#F4){ref-type="fig"}). Similar results were also obtained for the other acidic domain-containing cofactors (VPRBP, DAXX and PELP1), suggesting that the p53^KQ^ mutant recapitulates acetylation-mediated effects on p53 *in vivo*. Moreover, *p53^KQ/KQ^* MEFs displayed a severe proliferation defect ([Fig. 4f](#F4){ref-type="fig"}) and exhibited clear signs of senescence, including a flat and enlarged morphology with large multinucleated nuclei and marked senescence-associated beta-galactosidase (SA-β-Gal) staining ([Fig. 4g-h](#F4){ref-type="fig"}; [Extended Data Fig. 7g-h](#F11){ref-type="fig"}). In addition, Western blot analysis revealed a dramatic increase in the steady-state levels of p21 protein in *p53^KQ/KQ^* MEFs ([Fig. 4i](#F4){ref-type="fig"}). To directly address the role of SET *in vivo*, we generated *Set* mutant mice ([Extended Data Fig. 8a-b](#F12){ref-type="fig"}). Although the characterization of these mice was not complete ([Extended Data Fig. 8c-e](#F12){ref-type="fig"}), we prepared *Set^flox/flox^* MEFs for functional analysis. As shown in [Fig. 4j](#F4){ref-type="fig"}, upon Cre-mediated *Set* deletion, the expression of p53 target genes, such as p21 and Puma, was significantly induced, indicating SET as a critical regulator of p53 *in vivo*. Together, these data validate the critical role of CTD acetylation in p53 activation *in vivo*.

Previous studies showed that a p53^KR^ knockin mutant targeting the same CTD lysine residues does not significantly affect mouse development or p53 activities in mouse tissues or embryonic fibroblasts^[@R27],[@R28]^. Thus, loss of modifiable CTD lysines may neutralize the overall impact on p53 function by abrogating both negative and positive effects of regulation through the different types of CTD modifications. Surprisingly, p53^KQ^ knockin mice die shortly after birth with dramatic p53 activation. Like p53^KR^, p53^KQ^ also eliminates other types of modifications on these lysine residues; however, p53^KQ^ mimics the acetylated form while p53^KR^ resembles unacetylated p53. Thus, the striking difference between the phenotypes of p53^KQ^ and p53^KR^ mutant mice underscores the role of CTD acetylation *in vivo*.

The acidic domain-containing proteins in this study are referred to a specific group of proteins that harbor long clustered distribution of acidic amino acids. Searching the Uniprot database with our motif-finding algorithm^[@R29]^, we identified 49 polypeptides with highly acidic domains similar to SET, many of which are involved in transcriptional regulation and chromatin remodeling ([Extended Data Table 1](#T1){ref-type="table"}). In addition, by using Species-Specific Prediction of lysine (K) Acetylation program (SSPKA)^[@R30]^, we also identified 49 proteins containing a cluster of lysine residues that can potentially bind these acidic domains in an acetylation-modulated manner ([Extended Data Table 2](#T2){ref-type="table"}). Based on our data, we propose that acetylation-mediated regulation, whereby acetylation of p53 abrogates its association with the acidic domain-containing cofactors, can be expanded to a general mode of post-translational control for protein interactions that involve other acidic domain-containing factors and their acetylatable ligands.

Methods {#S1}
=======

General Data Reports {#S2}
--------------------

There is no statistical method to pre-evaluate the sample size in this study. The experiments (including animal related experiments) were not randomized. The investigators were not blinded to experiments. No samples/data were excluded except the xenograft mice with obvious unhealthy status.

Cell Culture, Plasmid Generation, Transfection and Reagent Treatment {#S3}
--------------------------------------------------------------------

H1299, U2OS, MCF7, H460 and HCT116 cell lines were cultured in DMEM medium with supplementing 10% (vol/vol) FBS. SU-DHL-5 cell line was cultured in IMDM medium with supplementing 10% (vol/vol) FBS. MEFs were cultured in DMEM medium with supplementing 10% (vol/vol) heat-inactivated FBS. All the cell lines were obtained from ATCC and have been proved as negative of mycoplasma contamination. No cell lines used in this work were listed in ICLAC database. The cell lines were freshly thawed from the purchased seed cells and were cultured for no more than 2 months. The morphology of cell lines were checked every week and compared with the ATCC cell line image to avoid cross-contamination or misuse of cell lines. SET stable knockdown cells were generated by lentivirus-based infection of shRNA. *SET* cDNA was purchased from Addgene (Plasmid\# 24998) and the full-length cDNA or the various fragments were sub-cloned into pWG-F-HA, pCMV-Myc or PGEX-2TL vectors. Each p53 plasmid was generated by sub-cloning human *p53* cDNA (including full-length or various fragments) into pWG-F-HA, pcDNA3.1 or PGEX-2TL vectors. The point-mutation constructs (including p53-KR and -KQ) were generated by using a site-directed mutagenesis Kit (Stratagene, 200521). Expressing construct and siRNA transfection were performed by Lipofectamine 2000 (Invitrogen, 11668-019) according to the manufacturer\'s protocol. To transfer oligos into SU-DHL-5 cells, electroporation was used by following Kit manufacture\'s protocol (Lonza PBC3-00675). DNA damage inducer Doxorubicin was used as 1 μM for 24 hours. Proteasome inhibitor Epoxomicin was used as 100 nM for 6 hours. Cells were treated with TSA (1 μM) and Nicotinamide (5 mM) for 6 hours to inhibit HDAC activity in the assays in which p53 acetylation needed to be maintained. Ad-GFP and Ad-Cre-GFP virus were purchased from Vector Biolabs (Cat. \#: 1761 and 1710).

Mouse Model {#S4}
-----------

To generate the knockin mice, W4/129S6 mouse embryonic stem (ES) cells (Taconic, Hudson, NY, USA) were electroporated with a targeting vector containing homologous regions flanking mouse p53 exon 11, in which all 7 lysines were mutated to glutamines (p53-KQ allele). A neomycin resistance gene cassette flanked by two LoxP sites (LNL) was inserted into intron 10 to allow selection of targeted ES cell clones with G418. ES cell clones were screened by Southern blotting with EcoRI-digested genomic DNA, using a probe generated from PCR amplification in the region outside the homologous region in the targeting vector. The correctly targeted ES cell clones containing the K to Q mutations were injected into C57BL/6 blastocysts, which were then implanted into pseudopregnant females to generate chimeras. Germline transmission was accomplished by breeding chimeras with C57BL/6 mice. Subsequently, mice containing the targeted allele were bred with Rosa26-Cre mice to remove the LNL cassette and to generate mice with only the K to Q mutations. To confirm the mutations inserted in *p53^+/KQ^* mice, we sequenced p53 cDNA derived from mRNA isolated from *p53^+/KQ^* MEFs. All seven K-to-Q mutations were confirmed and no additional mutations were found. The offspring were genotyped by PCR using a primer set (Forward: 5'-GGGAGGATAAACTGATTCTCAGA-3', Reverse: 5'- GATGGCTTCTACTATGGGTAGGGAT-3').

To generate a *Set* conditional knockout mouse, the exon2 of the Set gene is floxed and deletion of the exon2 results in a frameshift and the truncation of the C-terminal domain. The targeting vector of Set contains 10 kb genomic DNA spanning exon2, a neomycin resistance gene cassette and loxP sites are inserted flanking exon2. To increase targeting frequency, a Diphtheria toxin A cassette is inserted at the 3' end of the targeting vector to reduce random integration of the modified Set genomic DNA. A new Bgl II restriction site is also inserted to facilitate Southern blot screening. Among the 200 mouse ES cell clones screened, eight of them were identified to have integrated floxed exon2 by southern blot using a 5' probe, which detects a 14-kb band for wild type allele and an 11-kb band for the floxed exon2 allele (*Set^flox^*). Two of the clones were then injected into blastocysts to generate *Set* chimera mice and they were bred to produce germline transmission of the floxed exon2 allele. *Set^flox/+^* mice were intercrossed to generate set homozygote conditional knockout mice (*Set^flox/flox^*). Maintenance and experimental procedures of mice were approved by the Institutional Animal Care and Use Committee (IACUC) of Columbia University.

*In vitro* Binding Assay {#S5}
------------------------

For *in vitro* peptide binding assay: Equal amount of each synthesized biotin-conjugated peptide (made as column or as batch) was incubated with highly concentrated Hela nuclear extract (NE) or purified proteins for 1 hour or overnight at 4 °C. After washing with BC100 buffer (20 mM Tris-HCl pH 7.9, 100 mM NaCl, 10% Glycerol, 0.2 mM EDTA, 0.1% Triton X-100) for three times, the binding components were eluted by high-salt buffer (20 mM Tris-HCl pH 7.9, 1000 mM NaCl, 1% DOC, 10% Glycerol, 0.2 mM EDTA, 0.1% Triton X-100) or by boiling with 1× Laemmli buffer for further analysis. For *in vitro* GST-fusion protein binding assay: The *Escherichia coli* containing GST or GST-fusion protein expressing constructs were grew in the shaker at 37 °C until the O.D. 600 was about 0.6. And then 0.1 mM IPTG was added and incubated the *Escherichia coli* at 25 °C for 4 hours or overnight to induce GST or GST-fusion protein expression. After purification by GST·Bind™ Resin (Novagen, 70541), equal amount of immobilized GST or GST-fusion proteins were incubated with other purified proteins for 1 hour at 4 °C, followed by washing with BC100 buffer for three times. The binding components were eluted by boiling with 1× Laemmli buffer and subjected to western blot analysis.

Co-Immunoprecipitation Assay (Co-IP) {#S6}
------------------------------------

Whole cellular extract (WCE) were prepared by BC100 buffer plus sonication. Nuclear extract (NE) was prepared by sequentially lysing cells with HB buffer (20 mM Tris-HCl pH7.9, 10 mM KCl, 1.5 mM MgCl~2~, 1 mM PMSF, 1× protease inhibitor (Sigma); for cytosolic fraction) and BC400 buffer (20 mM Tris-HCl pH 7.9, 400 mM NaCl, 10% Glycerol, 0.2 mM EDTA, 0.5% Triton X-100, 1 mM PMSF, 1× protease inhibitor; for nuclear fraction). Carefully adjust the salt concentration of NE to 100 mM. 2 μg of indicated antibody (or 20 μl Flag M2 Affinity Gel (Sigma, A2220)) was added into WCE or NE and incubated overnight at 4 °C, followed by adding 20 μl Protein A/G agarose (Santa Cruz, sc-2003; only for IP by unconjugated antibody mentioned above) for 2 hours. After washing with BC100 buffer for three times, the binding components were eluted by Flag peptide (Sigma, F3290), by 0.1% Trifluoroacetic acid (TFA, Sigma, 302031) or by boiling with 1× Laemmli buffer and subjected to western blot assay.

Purification of Ub-, Sumo- or Nedd-p53 conjugates from cells {#S7}
------------------------------------------------------------

To prepare Ub-p53: H1299 cells were co-transfected with p53, Mdm2 and 6×HA-Ub expressing plasmids for 48 hours. The cells were lysed by Flag lysis buffer (50 mM Tris-HCl pH=7.9, 137 mM NaCl, 10 mM NaF, 1 mM Na~3~VO~4~, 10% Glycerol, 0.5 mM EDTA, 1% Triton X-100, 0.2% Sarkosyl, 0.5 mM DTT, 1 mM PMSF, 1× protease inhibitor) and total Ub-conjugated proteins were purified by anti-HA-agarose (Sigma, A2095) and eluted by 1×HA peptide (Sigma I2149). To prepare Sumo-p53 or Nedd-p53: H1299 cells were co-transfected with p53, Mdm2 (only for Nedd-p53 preparation) and 6×His-HA-Sumo1 or 6×His-HA-Nedd8 expressing plasmids for 48 hours. The cells were lysed by Guanidine lysis buffer (6 M guanidin-HCl, 0.1 M Na~2~HPO~4~, 6.8 mM NaH~2~PO~4~, 10 mM Tris-HCl pH=8.0, 0.2% Triton-X100, freshly supplemented with 10 mM β-mercaptoethanol and 5 mM imidazole) with mild sonication. After overnight pull-down by Ni^+^-NTA agarose (Qiagen 30230), the binding fractions were sequentially washed with Guanidine lysis buffer, Urea buffer I (8 M urea, 0.1 M Na~2~HPO~4~, 6.8 mM NaH~2~PO~4~, 10 mM Tris-HCl pH=8.0, 0.2% Triton-X100, freshly supplemented with 10 mM β-mercaptoethanol and 5 mM imidazole) and Urea buffer II (8 M urea, 18 mM Na~2~HPO~4~, 80 mM NaH~2~PO~4~, 10 mM Tris-HCl pH=6.3, 0.2% Triton-X100, freshly supplemented with 10 mM β-mercaptoethanol and 5 mM imidazole). Precipitates were eluted by Elution buffer (0.5 M imidazole, 0.125 M DTT). All purified proteins were dialyzed against BC100 buffer before applying to subsequent pull-down assay. After pull-down assay, the interaction between SET and each p53-conjugate was detected by western blot with anti-p53 (DO-1) antibody.

Mass Spectrometry Assay {#S8}
-----------------------

The protein complex was separated by SDS-PAGE and stained with GelCode Blue reagent (Pierce, 24592). The visible band was cut and digested with trypsin and then subjected to liquid chromatography (LC) MS/MS analysis.

Luciferase Assay {#S9}
----------------

A firefly reporter (p21-Luci reporter) and a Renilla control reporter were co-transfected with indicated expressing constructs into H1299 cells for 48 hours and the relative luciferase activity was measured by dual-luciferase assay protocol (Promega, E1910).

Electrophoretic Mobility Shift Assay (EMSA) {#S10}
-------------------------------------------

Highly purified p53 or SET was incubated with a ^32^p-labelled probe (160 bp) containing p53-binding element of *p21* promoter in 1× binding buffer (10 mM Hepes, pH 7.6, 40 mM NaCl, 50 μM EDTA, 6.25% Glycerol, 1 mM MgCl~2~, 1 mM Spermidine, 1 mM DTT, 50 ng/μl BSA, 5 ng/μl sheared single strand salmon DNA) for 20 minutes at room temperature (RT). For super-shift assay, α-p53 or α-SET antibody was pre-incubated with purified p53 or SET in the reaction system without probe for 30 minutes at RT and then added probe for further 20 minutes incubation. The complex was analyzed by 4% TBE-PAGE and visualized by autoradiography. The probe was obtained by PCR, labelled by T4 kinase (NEB, M0201S) and purified by Bio-Spin column (Bio-Rad, 732-6223).

Chromatin Immunoprecipitation (ChIP) Assay {#S11}
------------------------------------------

Cells were fixed by 1% formaldehyde for 10 minutes at RT and lysed with ChIP Lysis Buffer (50 mM Tris-HCl pH 8.0, 5 mM EDTA, 1% SDS, 1× protease inhibitor) for 10 minutes at 4 °C. After sonication, the lysates were centrifuged, and the supernatants were collected and pre-cleaned in Dilution Buffer (20 mM Tris-HCl pH 8.0, 2 mM EDTA, 150 mM NaCl, 1% Triton X-100, 1× protease inhibitor) by salmon sperm DNA saturated protein A agarose (Millipore, 16-157) for 1 hour at 4 °C. The pre-cleaned lysates were aliquot equally and incubated with indicated antibodies overnight at 4 °C. Saturated Protein A agarose was added into each sample and incubated for 2 h at 4 °C. The agarose was washed with TSE I (20 mM Tris-HCl pH 8.0, 2 mM EDTA, 150 mM NaCl, 0.1% SDS, 1% Triton X-100), TSE II (20 mM Tris-HCl pH 8.0, 2 mM EDTA, 500 mM NaCl, 0.1% SDS, 1% Triton X-100), Buffer III (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 0.25 M LiCl, 1% DOC, 1% NP40), and Buffer TE (10 mM Tris-HCl pH 8.0, 1 mM EDTA), sequentially. The binding components were eluted (1% SDS, 0.1 M NaHCO~3~) and performed reverse cross-link at 65 °C for at least 6 hours. DNA was extracted by PCR purification Kit (Qiagen, 28106). Real-time PCR was performed to detect relative enrichment of each protein or modification on indicated genes.

Cell Growth Assay {#S12}
-----------------

Approximate 1×10^5^ cells were seeded into 6-well plate with three replicates. The cell growth was monitored in consecutive days, as indicated, by using Countess™ automated cell counter (Invitrogen) or by staining with 0.1% crystal violet. For quantitative analysis of the crystal violet staining, the crystal violet was extracted from cells by 10% acetic acid and the relative cell number was measured by detecting the absorbance at 590 nm.

Xenograft Model {#S13}
---------------

1×10^6^ cells were mixed with Matrigel (Corning, 354248) as 1:1 ratio for total 200 ul volume. The cell-matrix complex was subcutaneously injected into the nude mice (NU/NU; 8-weeks old; female; strain 088; Charles River). After 3 weeks, the mice were sacrificed and the tumor weight was measured. The experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Columbia University. None of the experiments were limit exceeded for tumor burden (10% total bodyweight or 2 cm in diameter).

RT-qPCR {#S14}
-------

Total RNA was extracted by TRIzol (Invitrogen, 15596-026) and precipitated by ethanol. 1 μg of total RNA was reversed into cDNA by SuperScript® III First-Strand Synthesis SuperMix (Invitrogen, 11752-50). The relative expression of each target was measured by qPCR and the data were normalized by the relative expression of *GAPDH* or *β-Actin*.

Immunohistochemistry (IHC) {#S15}
--------------------------

FFPE sections of mouse brain tissue samples were stained with indicated antibodies and visualized by DAB exposure.

Protein Purification {#S16}
--------------------

The Flag tagged p53 or SET expressing construct was transfected into H1299 cells for 48 hours and the cells were lysed with Flag lysis buffer. After centrifuge, the Flag M2 Affinity Gel was added into supernatant and incubated 1 hour at 4 °C. After intensively washing by Flag Lysis Buffer for six times, the purified proteins were eluted with Flag peptide. For purification of acetylated p53, expressing construct CBP was co-transfected with p53 vector for 48 hours. TSA and Nicotinamide were added into the medium for the last 6 hours and the cells were harvested with Flag Lysis Buffer supplemented with TSA and Nicotinamide. The C-terminal unacetylated p53 was removed by p53-PAb421 antibody and then the acetylated p53 was purified as described above.

*In vitro* Acetylation Assay {#S17}
----------------------------

0.5 μg recombinant H3 was incubated with 20 ng purified p300 in 1×HAT buffer (50 mM Tris-HCl, pH 7.9; 1 mM DTT; 10 mM sodium butyrate, 10% glycerol) containing 0.1 mM Ac-CoA for 30 min at 30 °C. After reaction, the products were assayed by western blot with indicated antibodies. To measure the effect of SET on p300-mediated H3 acetylation, pre-incubate H3 and purified SET (1 μg) in 1×HAT buffer for 20 min at RT before adding other components for subsequent *in vitro* acetylation assay.

Generation of p53 Knockout (p53-KO) Cell Line by CRISPR/Cas9 Technique {#S18}
----------------------------------------------------------------------

Cells were transfected with constructs expressing Cas9-D10A (Nickase) and control sgRNAs or sgRNAs targeting p53 exon3 (Santa Cruz: sc-437281 for control; sc-416469-NIC for targeting p53). After 48 hours of transfection, cells were suspended, diluted and re-seeded to make sure single clone formation. More than 30 clones were picked up and the expression of p53 in each single clone was evaluated by western blot with both α-p53 (DO-1) and α-p53 (FL-393) antibodies. Further verification of the positive clones was done by sequencing the genomic DNA to make sure that the functional genomic editing happened (insertion or deletion-mediated frame-shift of p53 open reading frame (ORF)). Two (U2OS) or three (HCT116) clones were finally selected for subsequent experiments. The p53 knockout-mediated effect was verified to be reproducible in these independent clones. The targeting sequences of p53 loci for the sgRNAs were: 1) TTGCCGTCCCAAGCAATGGA; 2) CCCCGGACGATATTGAACAA.

RNA-Seq {#S19}
-------

U2OS (CRISPR Ctr or CRISPR p53-KO) cells were transfected with control siRNA or SET-specific siRNA (three oligos) for 4 days. Each sample group has at least two biological replicates. Total RNA was prepared by TRIzol reagent (Invitrogen, 15596-026). The RNA quality was evaluated by Bioanalyzer (Agilent) and confirmed that the RIN \> 8. Before performing RNA-seq analysis, a small aliquot of each sample was subjected to RT-qPCR analysis to confirm SET knockdown efficiency. RNA-seq analysis was performed at Columbia Genome Center. Specifically, from total RNA samples, mRNAs were enriched by poly-A pull-down and then preceded for library preparation by using Illumina TruSeq RNA prep kit. Libraries were then sequenced using Illumina HiSeq2000. Samples were multiplexed in each lane and yielded targeted number of single-end 100bp reads for each sample. RTA (Illumina) was used for base calling and bcl2fastq (version 1.8.4) was used for converting BCL to fastq format, coupled with adaptor trimming. Reads were mapped to a reference genome (Human: NCBI/build37.2) using Tophat (version 2.0.4). Relative abundance of genes and splice isoforms were determined using cufflinks (version 2.0.2) with default settings. Differentially expressed genes were tested under various conditions using DEseq, an R package based on a negative binomial distribution that models the number reads from RNA-seq experiments and test for differential expression. To further analyze the differentially expressed genes in a more reliable interval, the following filter strategies were applied: 1) the average of FPKM in either sample group \> 0.1; 2) the fold change between CRISPR Ctr/si-Ctr group and CRISPR Ctr/si-SET group \>2; 3) p value between CRISPR Ctr/si-Ctr group and CRISPR Ctr/si-SET group \<0.01.

To retrieve potentially known p53 target genes which were repressed by SET in a p53-dependent manner, we searched the filtered RNA-Seq result by following strategies: 1) the expression level in CRISPR Ctr/si-SET group was at least 2 fold higher than that in CRISPR Ctr/si-Ctr group; 2) the expression level in CRISPR Ctr/si-SET group was at least 2 fold higher than that in CRISPR p53-KO/si-SET group. The filtered genes which were also clearly verified as p53 target genes by literatures were collected and presented as Heatmap.

Bioinformatic Analysis {#S20}
----------------------

For Discovery of Acidic domains in the Human Proteome: Our motif finding algorithm initially searches for sequence motifs with a minimum acidic composition of 76% using a sliding window of 36 residues, as dictated by experimental results. Motifs found to be partially overlapping were merged into single motifs. Lastly, flanking non-acidic residues were cropped-out from the final motif. Motif discovery was carried out using the UniProt database, which contains 20,187 canonical human proteins manually annotated and reviewed. For prediction of proteins binding Acidic domain-containing proteins and regulated by acetylation: We identified proteins that can potentially bind long acidic domains in a similar way to p53: using a K-rich region whose binding properties can be regulated by acetylation. We used the training set assembled in SSPKA, which combines lysine acetylation annotations from multiple resources obtained either experimentally or in the scientific literature. This dataset lists all annotated acetylation sites for a given protein individually. We generated acetylation motifs with multiple acetylation sites by clustering those sites found to within a maximum distance of 11 residues in sequence. Following this, we searched for acetylation motifs with five or more lysines where at least three of them are annotated as acetylation sites.

Statistical Analysis {#S21}
--------------------

Results were shown as the means ± s.d.. Difference was determined by using a two-tailed, unpaired Student *t* test in all figures except those described below. In [Fig. 1g](#F1){ref-type="fig"}, difference was evaluated by one-way ANOVA with Bonferroni post hoc test. In [Fig. 2d and g](#F2){ref-type="fig"}, [Extended Data Fig. 2c](#F6){ref-type="fig"}, [Extended Data Fig. 3b and d](#F7){ref-type="fig"}, [Extended Data Fig. 4f](#F8){ref-type="fig"} and [Extended Data Fig. 7h](#F11){ref-type="fig"}, difference was measured by two-way ANOVA with Bonferroni post hoc test. All statistical analysis was performed by using GraphPad Prism software. *p* \< 0.05 was denoted as statistically significant.

Extended Data {#S22}
=============

![Further analysis of p53-SET interaction\
**a**, A list of SET peptides identified by mass spectrometry. **b**, *In vitro* binding assay of methylated p53 CTD and purified SET. **c**, **d**, **e**, *In vitro* binding assay between SET and purified ubiquitinated, sumoylated or neddylated form of p53. **f**, **g**, Western blot analysis of domains of p53 and SET for their interaction. *In vitro* binding assay was performed by incubating immobilized GST, GST-p53 or GST-SET with each purified SET or p53, as indicated. **h**, Western blot analysis of the interaction between p53 and SET in cells. H1299 cells were co-transfected with indicated expressing constructs and the nuclear extract was subjected to Co-IP assay. **i**, **j**, **k**, ChIP analysis of p53 or SET recruitment onto *PUMA* (**i**), *TIGAR* (**j**) or *GLS2* (**k**) promoter. HCT116 cells were treated with or without 1 μM doxorubicin for 24 hours and then the cellular extracts were subjected to ChIP assay by indicated antibodies. Asterisks indicate the specific bands of indicated proteins. Error bars indicate mean ± s.d., n=3 for technical replicates. Data were shown as representative of three experiments. Uncropped blots were shown in [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}.](nihms-811978-f0005){#F5}

![RNA-seq analysis to identify genes regulated by p53-SET interplay\
**a,** Western blot analysis of the expression of p53 in U2OS-derived CRISPR control cells or CRISPR p53-KO cells. **b,** Heatmap of genes regulated by p53-SET interplay. U2OS (CRISPR Ctr or CRISPR p53-KO) cells were transfected with control siRNA or SET-specific siRNA for 4 days and the total RNA were prepared for RNA-seq analysis with two or three biological replicates, as indicated. Known p53 target genes which were also repressed by SET in a p53-dependent manner were selected and presented as a Heatmap. The relative *SET* expression was shown in the last row of the Heatmap. **c,** qPCR validation of the genes regulated by p53-SET interplay. Error bars indicate mean ± s.d., n=3 for technical replicates. Data were shown as representative of three experiments. Uncropped blots were shown in [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}.](nihms-811978-f0006){#F6}

![SET-mediated effects on cell proliferation and tumor growth\
**a**, **b**, Representative image (**a**) or quantitative analysis (**b**) of SET knockdown-mediated effect on cell growth of U2OS-derived CRISPR control cells or CRISPR p53-KO cells. **c**, Western blot analysis of the expression of p53 in HCT116-derived CRISPR control cells or CRISPR p53-KO cells. **d**, Xenograft analysis of SET-mediated effect on tumor growth by HCT116-derived CRISPR control cells or CRISPR p53-KO cells. **e**, Western blot analysis of p53 expression in control or derived HCT116 cell lines, as indicated. Error bars indicate mean ± s.d., n=3 in (**b**) or n=5 in (**d**) for biological replicates. Uncropped blots were shown in [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}.](nihms-811978-f0007){#F7}

![SET regulates histone modifications on p53 target promoter\
**a**, Western blot analysis of SET knockdown-mediated effect on p53 C-terminal acetylation in HCT116 cells. Doxorubicin (Dox)-treated cells were also analyzed in parallel as a positive control. **b**, Western blot analysis of SET-mediated effect on CBP-induced p53 C-terminal acetylation in H1299 cells. **c**, **e**, ChIP analysis of promoter-recruitment of p53 (**c**) or p300/CBP (**e**) upon SET depletion in HCT116 cells. **d**, ChIP analysis of SET knockdown-mediated effect on histone modifications on *PUMA* promoter in HCT116 cells. **f**, ChIP analysis of SET-mediated effect on p53-dependent H3K18 and H3K27 acetylation on *PUMA* promoter. Error bars indicate mean ± s.d., n=3 for technical replicates. Data were shown as representative of three experiments. Uncropped blots were shown in [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}.](nihms-811978-f0008){#F8}

![Acetylation regulates the interaction between acidic-domain-containing proteins and their acetylatable ligands\
**a**, A summary table of characteristic features of acidic domain-containing protein SET, VPRBP, DAXX and PELP1. The acidic amino acids were underlined. **b**, *In vitro* binding assay of p53 CTD and purified full-length of VPRBP, DAXX or PELP1. **c**, **d**, **e**, Western blot analysis of the interaction between p53 and VPRBP (**c**), DAXX (**d**) or PELP1 (**e**) in nuclear fraction of H1299 cells. **f**, **g**, **h**, *In vitro* binding assay between purified SET and lysine-rich domain of H3 (**f**), KU70 (**g**) or FOXO1 (**h**). **i**, *In vitro* binding assay of H3 lysine-rich domain and purified VPRBP, DAXX or PELP1. **j**, *In vitro* binding assay of H3 lysine-rich domain and BRD4 or BRD7 (nuclear extract). Uncropped blots were shown in [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}.](nihms-811978-f0009){#F9}

![p53^KQ^ mutant mimics acetylated p53\
**a**, Schematic diagraph of human unacetylated p53, acetylation-deficient or acetylation-mimicking mutant of p53. **b**, *In vitro* binding assay of SET and different types of p53, as indicated. **c**, **d**, **e**, Western blot analysis of the interaction between acidic domain-containing proteins (**c,** VPRBP; **d,** DAXX; **e,** PELP1) and different types of p53 in cells. H1299 cells were co-transfected with indicated expressing constructs, and the nuclear extract was subjected to Co-IP assay. Asterisks indicate the purified proteins. Uncropped blots were shown in [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}.](nihms-811978-f0010){#F10}

![Generation of the *p53^KQ/KQ^* mice\
**a**, Schematic diagram of gene targeting strategy to replace p53 C-terminal 7 lysines with 7 glutamine in mouse *p53*. **b**, Southern blot screening of ES cells to identify *p53^+/KQ^* clones. **c**, PCR genotyping analysis of wildtype mouse (110 bps), *p53^+/KQ^* heterozygous mouse (110 bps and 150 bps), and *p53^KQ/KQ^* homozygous mouse (150 bps only). **d**, Sequencing analysis of the transcripts prepared from *p53^+/KQ^* heterozygous mouse spleen. **e**, A summary table of observed numbers from *p53^+/KQ^* heterozygous intercrosses. **f,** Positive control of p53 staining in IHC assay. The spleen tissue sections of *p53^+/+^* mice treated with or without 6 Gy γ-radiation was stained with p53 (CM-5) antibody. **g**, **h**, Representative image (**g**) or quantitative analysis (**h**) of SET knockdown-mediated cell growth of *p53^+/+^* or *p53^KQ/KQ^* MEFs (P2). Error bars indicate mean ± s.d., n=3 for biological replicates. Uncropped blots were shown in [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}.](nihms-811978-f0011){#F11}

![Characterization of Set conditional knockout mice\
**a,** Schematic diagraph of strategy to generate *Set* conditional knockout mice. **b,** Validation of *Set* knockout in embryos (E8.5) by genotyping and western blot analysis. **c,** A summary table of observed numbers from *Set^+/−^* intercrosses. **d,** Representative picture of *Set^+/+^* and *Set^−/−^* embryos (E10.5). **e,** qPCR analysis of the expression of p53 target genes in *Set^+/+^* and *Set^−/−^* embryos (E10.5). Error bars indicate mean ± s.d., n=3 for technical replicates. Data were shown as representative of three experiments. Uncropped blots were shown in [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}.](nihms-811978-f0012){#F12}

###### A list of human proteins containing acidic domain with a minimum percentage of acidic residues of 76% within a 36 residues-long window

Proteins are clustered into different categories depending on the biological process they are involved. Each protein is described by its UniProt accession code (1^st^ column), protein name (2^nd^ column) and a list of GO terms (5^th^ column). The corresponding acidic domains are described by their position in sequence (3^rd^ column) and their sequence (4^th^ column).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                        UniProtID   Protein Name                                                          Acidic Domain Position   Acidic Domain Sequence                     Biological Function (GO)
  --------------------------------------------------------------------------------------------------------------------- ----------- --------------------------------------------------------------------- ------------------------ ------------------------------------------ --------------------------------------------------------------------------------------------------------------------
  Proteins Involved in Gene Expression Control through DNA Binding, Transcription Regulation and Chromatin Remodeling   Q8IZL8\     Proline-, glutamic acid- and leucine-rich protein 1\                  886 - 963\               DEEEEEEEEEEEEEEEEEEEEEDFEEEEEDEEEYFEEEE\   Chromatin binding, Transcription factor binding, poly(A) RNA\
                                                                                                                        Q92688\     Acidic leucine-rich nuclear phosphoprotein 32 family\                 156 - 232\               EEEEEFEEEFEEEEGELEEEEEEEDEEEEEELEEVEDLE\   binding\
                                                                                                                        Q9UL68\     member B\                                                             107 - 169\               DSDAEVDGVDEEEEDEEGEDEEDEDDEDGEEEEFDEEDD\   Protein binding, Histone binding, RNA polymerase binding\
                                                                                                                        Q01538\     Myelin transcription factor 1-like protein\                           257 - 315\               EDEDVEGDEDDDEVSEEEEEFGLDEEDEDEDEDEEEEE\    Sequence-specific DNA binding, Transcription factor, Zinc binding\
                                                                                                                        A1YPR0\     Myelin transcription factor 1\                                        124 - 178\               EEYSEDNDEPGDEDEEDEEGDREEEEEIEEEDEDDDEDG\   Sequence-specific transcription factor, Zinc binding\
                                                                                                                        Q86V15\     Zinc finger and BTB domain-containing protein 7C\                     1671 - 1724\             EDVEDEEEEEEEEEEEEEEEENED\                  Nucleic acid binding, Metal ion binding\
                                                                                                                        Q01105\     Zinc finger protein castor\                                           236 - 289\               EEEDEEEEEEEEEEEEDEEEEEEEEEEEEEEEEEEEEEE\   DNA binding, Metal ion binding\
                                                                                                                        PODMEO\     Protein SET\                                                          248 - 301\               EEEEEEEEEEAAPDVIFQED\                      DNA binding, Histone binding, Phosphatase inhibitor\
                                                                                                                        Q7Z6M4\     Protein SETSIP\                                                       332 - 380\               EIMEPGGDGGEEDDKEDDDDDEDDDDEEDEEEEEEEEED\   Chromatin binding\
                                                                                                                        Q6PL18\     Transcription termination factor 4, mitochondrial\                    242 - 288\               DDDDTEDFADQENLPD\                          DNA binding, RNA binding, Protein binding\
                                                                                                                        Q9BTT0\     ATPase family AAA domain-containing protein 2\                        158 - 203\               ESSQEDEEEELELPEEEAEDDEDEDDDEDDDDEDDDEDD\   Histone binding, Chromatin binding, Hydrolase\
                                                                                                                        Q7Z6Z7\     Acidic leucine-rich nuclear phosphoprotein 32 family\                 2425 - 2469\             DDEDLRTDSEESLPE\                           Histone binding, Phophatase inhibitor activity\
                                                                                                                        Q12873-3\   member E\                                                             6-48\                    DMDDEEGEGEEDDDDDEEEEGLEDIDEEGDEDEGEEDED\   DNA binding, ligase activity, poly(A) RNA binding\
                                                                                                                        Q96KQ7\     E3 ubiquitin-protein ligase HUWE1\                                    289 - 331\               DDEGEEGEEDEGEDD\                           DNA binding, Helicase activity, poly(A) RNA binding\
                                                                                                                        Q8IX15\     Isoform 3 of Chromodomain-helicase-DNA-binding\                       507 - 549\               DDEEGGEDDDDDDDDGDEGEEELEDIDEGDEDEGEEDED\   Histone methyltransferase, p53 binding, C2H2 Zinc finger domain\
                                                                                                                        Q8WYB5\     protein 3\                                                            1062 - 1103\             DDEGEEGEEDEGEDD\                           DNA binding, Sequence-specific transcription factor, Transcription\
                                                                                                                        P19338\     Histone-lysine N-methyltransferase EHMT2\                             233 - 274\               DDKRASLDEDEDDDDEEDNDEDDNDEDDDDEDDDEAEDN\   co-repressor\
                                                                                                                        Q5H9L4\     Homeobox and leucine zipper protein Homez\                            326 - 367\               DEDEDDDEEE\                                DNA binding, Histone acyltransferase, Transcription factor binding\
                                                                                                                        Q13029\     Histone acetyltransferase KAT6B\                                      261 - 301\               ESSEEGEDQEHEDDGEDEDDEDDDDDDDDDDDDDDEDDE\   DNA binding, RNA binding, Protein binding\
                                                                                                                        P27797\     Nucleolin\                                                            368 - 407\               DEEDGEEE\                                  Transcription coactivator, Transcription factor binding, Histone\
                                                                                                                        Q9UER7\     Transcription initiation factor TFIID subunit 7-like\                 433 - 471\               EEEDDEDGDEDDEEEEENEAGPPEGYEEEEEEEEEEDED\   acyltransferase binding\
                                                                                                                        Q4LE39\     PR domain zinc finger protein 2\                                      528 - 566\               EDEDEDE\                                   DNA binding, sequence-specific DNA binding transcription factor, Zinc binding, histone-lysine N-methyltransferase\
                                                                                                                        Q9UPS6-2\   Calreticulin\                                                         1042 - 1079\             EDEDDSQDEEEEEEEDEEDDQEDDEGEEGDEDDDDDGSE\   androgen receptor binding, carbohydrate binding, complement\
                                                                                                                        P39687\     DAXX_HUMAN Death domain-associated protein 6\                         164 - 201\               MELDED\                                    component C1q binding\
                                                                                                                        P09429\     AT-rich interactive domain-containing protein 4B\                     178 - 214\               DEEEEEEEMVVSEEEEEEEEEGDEEEEEEVEAADEDDEE\   Androgen receptor binding, Heat shock protein binding, Histone\
                                                                                                                        Q9BT43\     SET1B_HUMAN Isoform 2 of Histone-lysine N-methyltransferase SETD1B\   157 - 192\               DDDE\                                      binding\
                                                                                                                        P17480\     AN32A_HUMAN Acidic leucine-rich nuclear\                              710 - 745\               EVEALTEQLSEEEEEEEEEEEEEEEEEEEEEEEEDEESG\   DNA binding, Protein binding, Transcription regulatory region DNA\
                                                                                                                        Q15911\     phosphoprotein 32 family member A\                                    453 - 488\               NQSD\                                      binding\
                                                                                                                        Q9UK99\     High mobility group protein B1\                                       417 - 451\               EVWCLDEEEEEEEEELPEDDEEEEEEEEEDDDDDDDDV\    Histone-lysine N-methyltransferase, Nuycleotide binding, RNA\
                                                                                                                        Q9Y4B6      DNA-directed RNA polymerase III subunit RPC7-like\                    1395 - 1429              IIQD\                                      binding\
                                                                                                                                    UBF1_HUMAN Nucleolar transcription factor 1\                                                   ELSKESSEEEEEEEDEEEEEEEEEEEEDEEEEEEEEEEE\   Gene expression, Intracellular signal transduction, nucleocytoplasmic transport\
                                                                                                                                    Zinc finger homeobox protein 3\                                                                EEE\                                       DNA binding, Protein binding, Transcription factor binding\
                                                                                                                                    F-box only protein 3\                                                                          VKE\                                       Gene expression, Innate immune response, RNA polymerase III\
                                                                                                                                    Protein VPRBP                                                                                  DSRSNNDDDEDEDDEDEDEDEDEDEDEDKEEEEEDCSEE\   activity\
                                                                                                                                                                                                                                   YLE\                                       poly(A) RNA binding, RNA pol I CORE element seq-specific DNA\
                                                                                                                                                                                                                                   EVHDLGEEEEEEEEEDEEEEEDDDDDELEDEGEEEASMP\   binding, RNA pol I upstream control element seq-specific DNA\
                                                                                                                                                                                                                                   NE\                                        binding\
                                                                                                                                                                                                                                   EEEEDKKRKEEEEAEDKEDDEDKDEDEEDEEDKEEDEEE\   DNA binding, sequence-specific DNA binding transcription factor, Protein binding\
                                                                                                                                                                                                                                   D\                                         ubiquitin-protein transferase activity\
                                                                                                                                                                                                                                   ETDDEDDEESDEEEEEEEEEEEEEATDSEEEEDLEQMQE\   Histone kinase, Ser/Thr kinase, Protein binding
                                                                                                                                                                                                                                   DETNKEEDEDDEEAEEEEEEEEEEEDEDDDDNNEEEEFE\   
                                                                                                                                                                                                                                   EEQESTEEEEEAEEEEEEEDDDDDDSDDRDESENDDED\    
                                                                                                                                                                                                                                   EGLDDEEEDEDEEEYDEDAQVVEDEEDEDEEEEGEEED\    
                                                                                                                                                                                                                                   EKSKKKKEEEEDEEDEEDEEEEEDEEDEDEEEDDDDE\     
                                                                                                                                                                                                                                   EEEVTSEEDEEKEEEEEKEEEEEEEYDEEEHEEETD\      
                                                                                                                                                                                                                                   ESSSEDESEDGDENEEDDEDEDDDEDDDEDEDNESE\      
                                                                                                                                                                                                                                   EKVEPAEEEAEEEEEEEEAEEEEEEEEEEEEEEEDE\      
                                                                                                                                                                                                                                   DEYEEMEEEEEEEEEEDEDDDSADMDE5DEDDEEE\       
                                                                                                                                                                                                                                   EDEDEEEDQEEEEQEEEDDDEDDDDTDDLDELDTD        

  DNA-related (Replication, Repair)                                                                                     P07199\     Major centromere autoantigen B\                                       403 - 446\               EGEEEEEEEEEEEEEEGEGEEEEEEGEEEEEEGGEGEEL\   Centromeric DNA binding, Chromatin binding, DNA binding\
                                                                                                                        P20962      Parathymosin                                                          504 - 537\               GEEEE\                                     DNA replication, Immune system process
                                                                                                                                                                                                          38 - 74                  EGGEDSDSDSEEEDDEEEDDEDEDDDDDEEDGDE\        
                                                                                                                                                                                                                                   EEEENGAEEEEEETAEDGEEEDEGEEEDEEEEEEDDE      

  RNA-related (Processing, Translation)                                                                                 Q96MU7\     YTH domain-containing protein 1\                                      198 - 264\               ENEEEGVEEDVEEDEEVEEDAEEDEEVDEDGEEEEEEEE\   poly(A) RNA binding, RNA binding\
                                                                                                                        O60841\     Eukaryotic translation initiation factor 5B\                          528 - 566\               EEEEEEEEEEEEYEQDERDQKEEGNDYD\              GTPase activity, poly(A) RNA binding, GTP binding\
                                                                                                                        P12270\     Nucleoprotein TPR\                                                    1948 - 1983\             ENPEEEEEEEEEEEEDEESEEEEEEEGESEGSEGDEEDE\   chromatin binding, heat shock protein binding, mRNA binding\
                                                                                                                        Q6ZU64\     Coiled-coil domain-containing protein 108\                            1768 - 1803\             DDEEEDDDENDGEHEDYEEDEEDDDDDEDDTGMGDE\      poly(A)RNA binding\
                                                                                                                        Q9NW13\     RNA-binding protein 28\                                               223 - 257\               EEEEEELEEEEEEEEETEEEELGKEEIEEKEEERDE\      nucleotide binding, poly(A) RNA binding\
                                                                                                                        Q9UQ88\     Cyclin-dependent kinase 11A\                                          291 - 323\               EEEDMEEEENDDDDDDDDEEDGVFDDEDEEEENIE\       ATP binding, cyclin-dependent protein ser/thr kinase\
                                                                                                                        P21127      Cyclin-dependent kinase 11B                                           303 - 335                EEEEEEEEEEEEEGSTSEESEEEEEEEEEEEEE\         ATP binding, cyclin-dependent protein ser/thr kinase, poly(A) RNA binding
                                                                                                                                                                                                                                   EEEEEEEEEEEEEGSTSEESEEEEEEEEEEEEE          

  Other                                                                                                                 Q5TCY1\     Tau-tubulin kinase 1\                                                 732 - 779\               EEEEEEEEDEEEEEEDEEEEEEEEEEEEEEEEEEEEEEE\   ATP binding, protein serine/threonine kinase activity\
                                                                                                                        P46060\     Ran GTPase-activating protein 1\                                      358 - 404\               AAAAVALGE\                                 GTPase activator activity\
                                                                                                                        Q5JTC6\     APC membrane recruitment protein 1\                                   369 - 410\               DDEDEEEEEEGEEEEEEAEEEEEEDEEEEEEEEEEEEEE\   beta-catenin binding, phosphatidylinositol-4,5-bisphosphate binding\
                                                                                                                        O60721\     Sodium/potassium/calcium exchanger 1\                                 854 - 894\               PQQRGQGE\                                  calcium, potassium:sodium antiporter activity, symporter activity\
                                                                                                                        P21817\     RYR1_HUMAN Ryanodine receptor 1\                                      1872 - 1911\             EEMALPDDDDEEEEEEEEVELEEEEEEVKEEEEDDDLEY\   Calcium ion channel, Calmoduling binding\
                                                                                                                        O43847      NRDC_HUMAN Nardilysin                                                 141 - 179                LWE\                                       Epidermal growth factor binding, Metalloendopeptidase, Zinc ion binding
                                                                                                                                                                                                                                   DGGDSEEEEEEEEEQEEEEEEEEQEEEEEEEEEEEEKGN\   
                                                                                                                                                                                                                                   EE\                                        
                                                                                                                                                                                                                                   EEEEEEDEEEEGEEEDEEEKEEDEEETAQEKEDEEKEEE\   
                                                                                                                                                                                                                                   E\                                         
                                                                                                                                                                                                                                   DDEEEEEVEEEEDDDEDSGAEIEDDDEEGFDDEDEFDDE    

  Function not clear                                                                                                    Q86TY3\     Uncharacterized protein C14orf37\                                     604 - 651\               DQLESEEGQEDEDEEDEEDEDEEEEDEEEDEEDKDADSL\   Membrane\
                                                                                                                        Q7L0X2\     Glutamate-rich protein 6\                                             16 - 63\                 DEGLDGDTE\                                 NA\
                                                                                                                        Q8TC90\     Coiled-coil domain-containing glutamate-rich protein 1\               301 - 344\               DQKESEEELEEEEEEEEVEEEEEEVEEEEEEVEEEEEEV\   NA\
                                                                                                                        P0C7V8      DDB1 - and CUL4-associated factor 8-like protein 2                    107 - 146                VEEELVGEE\                                 NA
                                                                                                                                                                                                                                   EEEEEVEDEEEEVEDEEEEEVEEAEYVEEGEEELEEEEL\   
                                                                                                                                                                                                                                   EEEEE\                                     
                                                                                                                                                                                                                                   EEETEREEEDEEIQEEGGEEEEEEEEEEEEEEEEEEEEE\   
                                                                                                                                                                                                                                   E                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### A List of human proteins containing lysine-rich domain with at least five lysines where three or more lysines are annotated as acetylation sites in the SSPKA database

Each protein is described by its UniProt accession code and their protein name (1^st^ and 2^nd^ column, respectively). Acetylated motifs are described by the position of their annotated acetylation sites contained and their sequence (3^rd^ and 4^th^ column, respectively).

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                   UniProt ID                                                  Protein Name                                       Acetylated Lysines                                             Sequence of Lysine-rich Domain
  -------------------------------------------------------------------------------- ----------------------------------------------------------- -------------------------------------------------- -------------------------------------------------------------- --------------------------------------
  Transcription Factor                                                             015525                                                      Transcription factor MafG                          53, 60, 71, 76                                                 EEIVQLKQRRRTLKNRGYAASCRVKRVTQKEELEKQ

  P18146                                                                           Early growth response protein 1                             422, 424, 425                                      KIHLRQKDKKADKSW                                                

  P52630                                                                           Signal transducer and activator of transcription 2          182, 184, 194, 197                                 RYKIQAKGKTPSLDPHQTKEQKILQETL                                   

  Q16236                                                                           Nuclear factor erythroid 2-related factor 2                 533, 536, 538, 541, 543, 548, 554, 555             QDLDHLKDEKEKLLKEKGENDKSLHLLKKQLSTLY                            

  Q9Y2Y9                                                                           Krueppel-like factor 13                                     166, 168, 180                                      LESPQRKHKCHYAGCEKVYGKSSHLKA                                    

  P04150                                                                           Glucocorticoid receptor                                     480, 492, 494, 495                                 PACRYRKCLQAGMNLEARKTKKKIKGIQ                                   

  P43694                                                                           Transcription factor GATA-4                                 312, 319, 321, 323                                 RPLAMRKEGIQTRKRKPKNLNKSK                                       

  P06733\*                                                                         Alpha-enolase                                               60, 71, 80, 89                                     KTRYMGKGVSKAVEHINKTIAPALVSKKLNVTEQEKIDKLMI                     

  P23769                                                                           Endothelial transcription factor GATA-2                     389, 390, 399, 403, 405, 406, 408, 409             NRPLTMKKEGIQTRNRKMSNKSKKSKKGAECFE                              

  Transcriptional Regulation (Except Transcription Factor), Chromatin Remodeling   060563                                                      Cyclin-T1                                          380, 386, 390                                                  SQKQNSKSVPSAKVSLKEYRAKH

  P04406\*                                                                         Glyceraldehyde-3-phosphate dehydrogenase                    251, 254, 259, 260                                 LTCRLEKPAKYDDIKKWKQAS                                          

  P06748\*                                                                         Nucleophosmin                                               141, 150, 154, 155                                 LLSISGKRSAPGGGSKVPQKKVKLAAD                                    

                                                                                                                                               250, 257, 267, 273                                 VEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMT                           

  P09874                                                                           Poly \[ADP-ribose\] polymerase 1                            498, 505, 508                                      WAPRGKSGAALSKKSKGQVKEE                                         

  P19338                                                                           Nucleolin                                                   70, 79, 87\                                        VWSPTKKVAVATPAKKAAVTPGKKAAATP\                                 
                                                                                                                                               102, 109, 116, 124, 132                            KTVTPAKAVTTPGKKGATPGKALVATPGKKGAAIPAKGAKNGK                    

  P51531                                                                           Probable global transcription activator SNF2L2              996, 997, 999, 1003\                               DGSEKDKKGKGGAKTLMNTI\                                          
                                                                                                                                               1547, 1551, 1553, 1555, 1556                       LNKKDDKGRDKGKGKKRPNRGK                                         

  Q00987                                                                           E3 ubiquitin-protein ligase Mdm2                            466, 467, 469, 470                                 ACFTCAKKLKKRNKPCP                                              

  Q13547                                                                           Histone deacetylase 1                                       432, 438, 439, 441                                 EGEGGRKNSSNFKKAKRVKTED                                         

  Q92793                                                                           CREB-binding protein                                        1797, 1806, 1809\                                  SLPSCQKMKRWQHTKGCKRKTNGG\                                      
                                                                                                                                               1583, 1586, 1587, 1588, 1591, 1592, 1595, 1597     G3QGDSKNAKKKNNKKTNKNKSSISRA                                    

  Q92831                                                                           Histone acetyltransferase KAT2B                             416, 428, 430, 441, 442                            SSSPACKASSGLEANPGEKRKMTDSHVLEEAKKPRVMGD                        

  P27695\*                                                                         DNA-(apurinic or apyrimidinic site) lyase                   24, 27, 31, 32, 35                                 RTEPEAKKSKTAAKKNDKEAAGEG                                       

  P62805                                                                           Histone H4                                                  6, 9, 13, 17, 21, 32                               MSGRGKGGKGLGKGGAKRHRKVLRDNIQGITKPAIRRL                         

  Q92922                                                                           SWI/SNF complex subunit SMARCC1                             345, 346, 354, 359                                 SRKKSGKKGQASLYGKRRSQKEEDEQE                                    

  P26358                                                                           DNA (cytosine-5)-methyltransferase 1                        1111, 1113, 1115, 1117, 1119, 1121                 SPGNKGKGKGKGKGKPKSQACEP                                        

  Q13569                                                                           G/T mismatch-specific thymine DNA glycosylase               83, 84, 87                                         KKPVESKKSGKSAKSKE                                              

  Q8TEK3                                                                           Histone-lysine N-methyltransferase, H3 lysine-79 specific   397, 398, 401                                      PSKARKKKLNKKGRKMA                                              

  Q92841                                                                           Probable ATP-dependent RNA helicase DDX17                   108, 109, 121, 129                                 GGGLPPKKFGNPGERLRKKKWDLSELPKFEKNEY                             

  P68431                                                                           Histone H3.1                                                5, 10, 15, 19, 24, 28, 37, 38                      MARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKKPHRYRP                   

  Q92522                                                                           Histone H1x                                                 179, 182, 185                                      KKGAGAKKDKGGKAKKTAA                                            

  P46100                                                                           Transcriptional regulator ATRX                              1933, 1935, 1936, 1939                             YTKKKKKGKKGKKDSSSSG                                            

  Q6DN03                                                                           Putative histone H2B type 2-C                               13, 16, 17, 21, 24                                 FAPAPKKGSKKAVTKAQKKDGKKR                                       

  P05114                                                                           Non-histone chromosomal protein HMG-14                      3, 5, 14, 18, 27, 31, 38, 42, 48, 53, 55, 59, 61   MPKRKVSSAEGAAKEEPKRRSARLSAKPPAKVEAKPKKAAAKDKSSDKKVQTKGKRGAK\   
                                                                                                                                                                                                  GKQAEVAN                                                       

  DNA Repair and Integrity                                                         P12956                                                      X-ray repair cross-complementing protein 6         539, 542, 544, 553, 556                                        DYNPEGKVTKRKHDNEGSGSKRPKVEYSEE

  Q9UQE7                                                                           Structural maintenance of chromosomes protein 3             105, 106, 113, 114                                 RRVIGAKKDQYFLDKKMVTKND                                         

  P27695\*                                                                         DNA-(apurinic or apyrimidinic site) lyase                   24, 27, 31, 32, 35                                 RTEPEAKKSKTAAKKNDKEAAGEG                                       

  Other DNA Related Function                                                       094761                                                      ATP-dependent DNA helicase Q4                      376, 380, 382, 385, 386                                        RSRLLRKQAWKQKWRKKGECFGG

  Ribosome Biogenesis                                                              P06748\*                                                    Nucleophosmin                                      141, 150, 154, 155\                                            LLSISGKRSAPGGGSKVPQKKVKLAAD\
                                                                                                                                                                                                  250, 257, 267, 273                                             VEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMT

  Specific Molecular/Biological Function Uncertain                                 P81534                                                      Beta-defensin 103                                  48, 54, 61, 66, 67                                             VLSCLPKEEQIGKCSTRGRKCCRRKK

  Q3BBV0                                                                           Neuroblastoma breakpoint family member 1                    1101, 1103, 1105, 1106                             VGEIEKKGKGKKRRGRRS                                             

  Q8N7X0                                                                           Androglobin                                                 337, 340, 343                                      KDGKEVKDVKEFKPESSLT                                            

  Q6ZQR2                                                                           Uncharacterized protein C9orf171                            237, 240, 246                                      EQKATQKAIKLEKKQKWLGKL                                          

  Others                                                                           P04406\*                                                    Glyceraldehyde-3-phosphate dehydrogenase           251, 254, 259, 260                                             LTCRLEKPAKYDDIKKWKQAS

  P09622                                                                           Dihydrolipoyl dehydrogenase, mitochondrial                  267, 271, 273, 277                                 FQRILQKQGFKFKLNTKVTGATK                                        

  P40939                                                                           Trifunctional enzyme subunit alpha, mitochondrial           350, 353, 359                                      HGQVLCKKNKFGAPQKDVKHLA                                         

  Q9NP61                                                                           ADP-ribosylation factor GTPase-activating protein 3         223, 228, 229                                      KPNQAKKGLGAKKGSLGAQ                                            

  Q9Y6F6                                                                           Protein MRVI1                                               398, 402, 405                                      EKRFAGKAGGKLAKAPGLKD                                           

                                                                                                                                               205, 214, 223, 229, 236                            AACLLPKLDE LRDEGKASSAKQRLKCASLQKFGERAFKAWAVAR                  

  P02768                                                                           Serum albumin                                               543, 548, 560, 565, 569, 581, 584, 588, 597, 598   ICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEE\   
                                                                                                                                                                                                  GKKLVAASQ                                                      

  P62328                                                                           Thymosin beta-4                                             4, 12, 15                                          MSDKPDMAEIEKFDKSKLKKT                                          

  Q13576                                                                           Ras GTPase-activating-like protein IQGAP2                   1467, 1471, 1474                                   SIKLDGKGEPKGAKRAKPVK                                           

  Q15283                                                                           Ras GTPase-activating protein 2                             208, 209, 211                                      PSRNDQKKTKVKKKTS                                               

  Q99075                                                                           Proheparin-binding EGF-like growth factor                   96, 97, 99, 104                                    EHGKRKKKGKGLGKKRDPCLR                                          

  P06733\*                                                                         Alpha-enolase                                               60, 71, 80, 89                                     KTRYMGKGVSKAVEHINKTLAPALVSKKLNVTEQEKIDKLMI                     

  P15692                                                                           Vascular endothelial growth factor A                        142, 147, 149, 152                                 RARQEKKSVRGKGKGQKRKRKKS                                        

  P10636                                                                           Microtubule-associated protein tau                          571, 574, 576, 584, 591, 597, 598, 607, 615        VPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGG      
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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![Identification of SET as a specific co-repressor of C-terminal unacetylated p53\
**a**, Schematic diagraph of synthesized biotin-conjugated p53 CTD. **b**, Coomassie Blue staining of the protein complex bound with p53 CTD. **c**, Schematic diagraph of SET. DD: dimerization domain; ED: earmuff domain; AD: acidic domain. **d**, *In vitro* binding assay of p53 CTD and purified SET. **e**, Western blot analysis of the interaction between p53 and SET in nuclear fraction of H1299 cells. **f**, EMSA showing SET/p53-DNA complex formation *in vitro*. **g**, Luciferase assays of SET-mediated regulation on p53 transactivity in H1299 cells. **h**, Western blot analysis of the endogenous interaction between p53 and SET upon doxorubicin (Dox) treatment in HCT116 cells. **i**, ChIP analysis of p53 or SET recruitment on *p21* promoter upon Dox treatment in HCT116 cells. **j**, A model of dynamic promoter-recruitment of SET regulated by p53 CTD acetylation status. Error bars indicate mean ± s.d., n=3 for technical replicates. Data were shown as representative of three experiments. Uncropped blots were shown in [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}.](nihms-811978-f0001){#F1}

![SET negatively regulates p53 transactivity by inhibiting p300/CBP-mediated H3K18 and H3K27 acetylation on p53 target promoter\
**a**, **b**, **c** Western blot analysis of SET knockdown-mediated effect on p53 activity in cells. **d**, Xenograft analysis of SET-mediated effect on tumor growth. **e**, ChIP analysis of SET knockdown-mediated effect on histone modifications at *p21* promoter in HCT116 cells. **f**, *In vitro* acetylation assay of SET effect on p300-mediated H3K18 and H3K27 acetylation. **g**, ChIP analysis of SET-mediated effect on p53-dependent H3K18 and H3K27 acetylation on *p21* promoter in H1299 cells. **h**, A model of SET-mediated regulation on p53 transactivity. Error bars indicate mean ± s.d., n=3 for technical replicates in (**e**) and (**g**); n=5 (*p53^+/+^* group) or n=3 (*p53^−/−^* group) for biological replicates in (**d**). Data were shown as representative of three experiments. Uncropped blots were shown in [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}.](nihms-811978-f0002){#F2}

![Acidic domain-containing proteins represent a new class of "reader" for their unacetylated ligands\
**a**, Schematic diagraph of acidic domain (AD)-containing protein SET, VPRBP, DAXX and PELP1. **b**, **c**, **d**, *In vitro* binding assay of p53 CTD and acidic domain of VPRBP (**b**), DAXX (**c**) or PELP1 (**d**). **e**, Schematic diagraph of lysine-rich domain (KRD)-containing protein histone H3, KU70 and FOXO1. **f**, **g**, **h**, *In vitro* binding assay between purified SET acidic domain and lysine-rich domain of H3 (**f**), KU70 (**g**) or FOXO1 (**h**). **i**, A model of acetylation-dependent regulation of the interactions between lysine-rich domain (KRD)-containing proteins and their acidic domain (AD)-containing "readers". Uncropped blots were shown in [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}.](nihms-811978-f0003){#F3}

![The physiological significance of acetylation-dependent dissociation of p53 from its acidic domain-containing "readers"\
**a**, The new born of *p53^+/+^* and *p53^KQ/KQ^* mice. **b**, The brains from *p53^+/+^* and *p53^KQ/KQ^* mice. **c**, Immunohistochemistry analysis of brain sections from *p53^+/+^* and *p53^KQ/KQ^* mice. **d**, RT-qPCR analysis of p53 target gene expression in *p53^+/+^* and *p53^KQ/KQ^* tissues. **e**, Western blot analysis of the interaction between p53 and acidic domain-containing proteins in *p53^+/+^* or *p53^KQ/KQ^* MEFs treated with proteasome inhibitor Epoxomicin. **f**, Cell growth analysis of *p53^+/+^* or *p53^KQ/KQ^* MEFs (P3). **g**, Morphological representative of *p53^+/+^* and *p53^KQ/KQ^* MEFs from P0 to P4. **h**, SA-β-gal staining of *p53^+/+^* and *p53^KQ/KQ^* MEFs (P3). **i**, Western blot analysis of p21 and p53 expression in *p53^+/+^* and *p53^KQ/KQ^* MEFs. **j,** Western blot analysis of p53 targets in *Set* conditional knockout MEFs. Error bars indicate mean ± s.d., n=3 for technical replicates in (**d**); n=3 for biological replicates in (**f**). Data were shown as representative of three experiments. Uncropped blots were shown in [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}.](nihms-811978-f0004){#F4}
